Signed technology transfer agreement with Celltrion for 3 microbiome drug candidates: total deal up to KRW 205.2 billion (upfront KRW 1 billion received, milestones KRW 204.2 billion, plus royalties).
Consolidated Q1 2026 revenue: KRW 19.2 billion (+11% YoY), operating loss KRW 2.7 billion, net loss KRW 0.2 billion (vs loss of KRW 2.6 billion in Q1 2025).
KBLP-001 (psoriasis) Phase 2 completed with CSR; KBLP-002 (asthma/atopic) Phase 1 completed; KBLP-010 (autism) human trial ongoing.
Subsidiary WeBiome contributed KRW 18.5 billion in health functional food sales (96% of total revenue), providing stable cash flow.
Cash and equivalents KRW 7.1 billion, short-term financial instruments KRW 39 billion, total current assets KRW 60.2 billion – strong liquidity.